The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats.

The aim of this study was to synthesize folate-dendrimer conjugates as suitable vehicle for site specific delivery of anti-arthritic drug (indomethacin) to inflammatory regions and to determine its targeting efficiency, biodistribution in adjuvant induced arthritic rats. Folic acid was coupled to the surface amino groups of G4-PAMAM dendrimer (G4D) via a carbodiimide reaction and loaded with indomethacin. The conjugates were characterized by (1)H-NMR and IR spectroscopy. The drug content and percent encapsulation efficiency increased with increasing folate content for the dendrimer conjugates. The in vitro release rate was decreased for the folate conjugates when compared with unconjugated dendrimer (DNI). The plasma concentration profile showed a biphasic curve indicating rapid distribution followed by slow elimination. The AUC(0-infinity), half-life and residence time of indomethacin in inflamed paw was higher for folate-dendrimer conjugates. The time-averaged relative drug exposure (r(e)) of the drug in paw and overall drug targeting efficiency (T(e)) were higher for folate conjugate with 21 folate moieties (4.1 and 2.78, respectively) when compared with DNI (1.91 and 1.88, respectively). This study demonstrated the superiority of active targeting over dendrimer mediated passive targeting and also for the first time, folate-mediated targeting of an anti-arthritic drug to the inflammatory tissues.

[1]  P. Saigo,et al.  Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. , 1993, The American journal of pathology.

[2]  B. Newbould,et al.  CHEMOTHERAPY OF ARTHRITIS INDUCED IN RATS BY MYCOBACTERIAL ADJUVANT. , 1963, British journal of pharmacology and chemotherapy.

[3]  R. Müller,et al.  Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. , 2003, Bioconjugate chemistry.

[4]  E C Wiener,et al.  Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. , 1997, Investigative radiology.

[5]  Philip S Low,et al.  Folate-mediated delivery of macromolecular anticancer therapeutic agents. , 2002, Advanced drug delivery reviews.

[6]  M. Brechbiel,et al.  Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. , 1999, Bioconjugate chemistry.

[7]  K. Kono,et al.  Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. , 2000, Bioconjugate chemistry.

[8]  E. Pretsch.  Tables of spectral data for structure determination of organic compounds , 1983 .

[9]  J. Baker,et al.  Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Anil K Patri,et al.  Dendritic polymer macromolecular carriers for drug delivery. , 2002, Current opinion in chemical biology.

[11]  T. Nakamura,et al.  Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[12]  J. Baker,et al.  Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. , 1996, Nucleic acids research.

[13]  Narendra Kumar Jain,et al.  Solubility Enhancement of Indomethacin with Poly(amidoamine) Dendrimers and Targeting to Inflammatory Regions of Arthritic Rats , 2004, Journal of drug targeting.

[14]  B. Bloom.  Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. , 1988, The American journal of medicine.

[15]  F. Wolfe,et al.  The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. , 1998, The Journal of rheumatology.

[16]  S Sridevi,et al.  Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[17]  P. Diwan,et al.  Long-circulating liposomes of indomethacin in arthritic rats--a biodisposition study. , 2000, Pharmaceutica acta Helvetiae.

[18]  D. Tomalia,et al.  Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. , 2001, Drug discovery today.

[19]  Philip S Low,et al.  Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. , 2004, Advanced drug delivery reviews.

[20]  P. Srinath,et al.  Pharmacodynamic and pharmacokinetic evaluation of lipid microspheres of indomethacin. , 1998, Pharmaceutica Acta Helvetiae.

[21]  T. Littler.  Anti-rheumatic drugs. , 1983, Pharmacology & therapeutics.

[22]  M. Brechbiel,et al.  Biodistribution of a 153Gd-Folate Dendrimer, Generation = 4, in Mice With Folate-Receptor Positive and Negative Ovarian Tumor Xenografts , 2002, Investigative radiology.

[23]  Lars T. Piehler,et al.  Slab-gel and capillary electrophoretic characterization of polyamidoamine dendrimers , 1998 .